The following changes apply to APWU Health Plan members who live in Louisiana, Mississippi, or the following counties in Alabama: Baldwin, Bibb, Choctaw, Clarke, Colbert, Conecuh, Dallas, Escambia, Fayette, Franklin, Greene, Hale, Lamar, Lauderdale, Lawrence, Marengo, Marion, Mobile, Monroe, Perry, Pickens, Sumter, Tuscaloosa, Walker, Washington, Wilcox, and Winston.
High Option and Consumer Driven Option members
APWU Health Plan will:
Relax plan requirements to assist you with care received 8/29 – 9/30/2021.
Waive refill “too soon” limitations on supplies and medications for members who are unable to use the mail order service for refills or experience lost or destroyed medications.
For care received 8/29 – 9/30/2021, APWU Health Plan will provide the following:
Access to care: Members who have been displaced from their homes or whose network provider or medical facility is inaccessible can access care anywhere, as needed, and it will be covered at the in-network benefit level.
Prescription medications: Members who need help obtaining early prescription refills may work with a pharmacy that can obtain an override on their behalf, or they can contact the Customer Care number on the back of their ID card. For mail-order delivery service to affected areas or any other questions related to prescriptions, members can contact the pharmacy number on the back of their ID card and discuss their situation for help obtaining a local supply, if necessary, and more.
For additional assistance: Members can call the Customer Care number on the back of their medical ID card if they need additional assistance. If they have misplaced their medical ID card, call 1-866-633-2446, 8 a.m. – 8 p.m. (in the local time zone), Monday – Friday, or visit uhcretiree.com to request a new ID card and print a temporary ID card to use until the new card arrives.
Emotional support for all
Optum offers a free emotional support help line for affected individuals.
It was wonderful to represent the Health Plan at the North Carolina, South Carolina, and Georgia Tri-State American Postal Worker’s Conference. The conference was held from May 13 through May 16, 2021. The conference was attended by over 150 people.
The APWU Health Plan setup temperature monitoring stations for the conference attendees. The infrared thermometers allowed attendees to regularly check on their health before participating in the conference. These monitoring stations were a great success. Thank you to North Carolina Council President Tony D. McKinnon Sr. and the host local for doing a fantastic job, making the environment safe and comfortable for all those in attendance.
The Health Plan will offer temperature monitoring at two more upcoming events the Denver Regional APWU Conference scheduled from June 03 through June 06, 2021 and the National President’s Conference from June05 through June 07, 2021.
Congratulations on your marriage! You have 60 days from your marriage date to add your spouse to your insurance policy. If you miss this deadline you have to wait to add them until the next insuranceOpen Season or until another qualifying life event allows you to make a change.
You will need to submit proof of your marriage to your payroll office. Typically they require the marriage certificate, along with the enrollment forms. They require this proof to confirm that your spouse is eligible to be on your plan and that you are allowed to make a change to your insurance outside the normal time frame.
Your payroll office will process the insurance enrollment form, change your premium withholding, and notify the health plan of the change. Once the paperwork is processed you will receive a letter or a digital onscreen confirmation of the date that your spouse’s coverage will start.
TUESDAY, Sept. 22, 2020 (HealthDay News) — The best time to get your flu shot is now if you want to protect yourself against a potential “twindemic” infection of influenza and COVID-19, experts say.
“Early September, at the very least early October, is the best time to get your flu shot. That really allows your body to build up the appropriate immune response in time for the peak prevalence of influenza in the community,” Dr. Nadia Eltaki, director of clinical operations for Sibley Memorial Hospital in Washington, D.C., said during an HD Live! interviewon Tuesday.
A massive effort is underway to get as many people as possible inoculated with the seasonal flu vaccine, to reduce the risk of combination influenza/COVID-19 epidemics overwhelming local or regional health systems in the United States.
The “twindemic” risk to individuals is twofold, Eltaki said.
Infection with either virus will deal your immune system such a blow that you will be more susceptible to a more savage follow-up bout with the other, Eltaki said.
“One virus can weaken your immune system enough to make you susceptible to the other virus or any other respiratory virus or illness,” Eltaki said. Your body will be less able to stave off initial infection or to hold the line against a cascading viral onslaught throughout your body, she said.
Worse, some people could be unlucky enough to contract both viruses at the same time, Eltaki added.
“Unfortunately, it is possible to contract both the influenza virus and the novel coronavirus,” she said. “If you are infected with both viruses together, the resulting impact could lead to even more severe outcomes than either infection independently.”
The flu and COVID have strikingly similar symptoms, including fever, runny nose, sore throat, cough, body aches, headaches and GI upset, Eltaki said. The only major symptom that definitely points toward COVID rather than flu is the loss of smell and taste.
“We ask that if you have any of those symptoms to call your physician, explain your symptoms and self-quarantine until you know exactly what you have,” Eltaki said.
Public outreach regarding the importance of this year’s flu shot is crucial. Doctors have seen a decline in immunizations, health screenings and other types of patient visits, because people are afraid they’ll contract COVID-19 if they go to a doctor, Eltaki said.
Doctor’s offices and clinics have put a number of infection-control measures in place to protect people, she said. These include pre-appointment screening questionnaires, universal masking of patients and staff, temperature screenings upon arrival, and strict disinfecting procedures between patients.
People still not reassured by these measures have other options, Eltaki added. Major grocery store and commercial pharmacy chains not only offer quick and easy flu shots, but some have been offering coupons or gift cards for people who get the shot during their shopping trip.
Some folks also might be reluctant to get the flu shot because of some of the myths that have cropped up around the inoculation, Eltaki noted.
The most common misperception is that you’ll get the flu from the flu shot.
“The flu shot is made from a dead virus. You cannot get the flu from getting the flu shot,” Eltaki said.
“However, you can experience some symptoms, which is the result of your body mounting an immune response,” Eltaki continued. “You may have a low-grade fever or body aches, but that’s not the flu, that’s just your body matching the appropriate immune response to the flu shot.”
There also is no evidence that a flu shot increases a person’s risk of contracting COVID-19 or any other respiratory virus, the U.S. Centers for Disease Control and Prevention said.
Flu shots are needed every year because influenza virus mutates so quickly that humans cannot mount a lasting preventive immunity against it.
Each year, doctors make their best prediction regarding the strains of flu most likely to circulate widely in humans. The annual flu vaccine protects against either three or four of the leading contenders, depending on which vaccine you get.
“Studies have shown that the influenza vaccine is about 60% effective in preventing the flu,” Eltaki said. “Even though those odds are fair, we know if you do get the flu and you have received the flu shot, the severity, length, intensity and duration of your symptoms will still be less than the person who has not received a flu shot and gets the flu. There is some protective effect.”
You should get the flu shot rather than the nasal spray vaccine, Eltaki added.
“More and more, health care practitioners are steering away from the nasal mist because of presumed better efficacy of the shot,” she said. “Any child above the age of 6 months should get a flu shot.”
Pregnant women, the elderly and the immune-compromised also would do better with a flu shot than the nasal spray, Eltaki said.
By Robin Foster and E.J. Mundell HealthDay Reporters
THURSDAY, Sept. 17, 2020 (Healthday News) — The details of a plan to rapidly deliver a future coronavirus vaccine to Americans were unveiled by federal officials on Wednesday.
Two of the key parts of the plan are to begin distributing a vaccine with 24 hours of any approval or emergency authorization and offering the vaccine for free, The New York Times reported.
Officials from Operation Warp Speed — the multiagency effort to quickly vaccinate Americans against coronavirus — also said the timing of a vaccine was still unclear, the Times reported. That despite repeated statements from President Donald Trump that a shot could be ready before the election on Nov. 3.
“We’re dealing in a world of great uncertainty. We don’t know the timing of when we’ll have a vaccine, we don’t know the quantities, we don’t know the efficacy of those vaccines,” Paul Mango, the deputy chief of staff for policy at the U.S. Department of Health and Human Services, told the Times. “This is a really quite extraordinary, logistically complex undertaking, and a lot of uncertainties right now. I think the message we want you to leave with is, we are prepared for all of those uncertainties.”
Who will get the vaccine first? Initial distribution of a vaccine, possibly on an emergency basis, would to a limited group of high-priority people, such as health care workers, in the final three months of this year and into next year, the Times reported. The Department of Defense is providing logistical support for shipping and storing the vaccine, and for keeping track of who has gotten a vaccine and whether they got the full two doses, the newspaper said.
To achieve this, existing databases would be linked up so that, for example, a patient who received a vaccine at a public health center in January could go to a CVS pharmacy 28 days later in another state and be assured of getting the second dose of the right vaccine, the Times reported.
Right now, three drug makers are testing vaccine candidates in late-stage trials in the United States. One of those companies, Pfizer, has said that it could apply for emergency authorization as early as October, while the other two, Moderna and AstraZeneca, have said they hope to have something before the end of the year.
In a sign that the Pfizer vaccine trials are moving along smoothly, German pharmaceutical company BioNTech, which is developing a coronavirus vaccine with Pfizer, announced Thursday it was buying a new production plant so it can ramp up production of a COVID-19 vaccine when needed, CNN reported.
The vaccine plant in Marburg, Germany, would produce tens of millions more vaccine doses a month — pending regulatory approval, CNN reported. The plant should be up and running by the first half of 2021, BioNTech said in a statement, and the company will retain a highly skilled workforce of 300 employees following the transfer of the plant from Novartis later this year.
“In full production operations the production plant will increase BioNTech’s capacity to produce vaccines by about 750 million doses per year or more than 60 million doses per month,” BioNTech said.
New Drug May Help Prevent Severe COVID
A single infusion of an experimental drug dramatically lowers levels of coronavirus in the bodies of newly infected patients and cuts their chances of hospitalization, the drug’s maker reported Wednesday.
Eli Lilly’s announcement did not include detailed data and hasn’t been peer-reviewed or published yet, the Times reported.
The news comes from interim results of a trial sponsored by Eli Lilly and the U.S. National Institutes of Health. NIH officials would not comment on the announcement until they have seen more detailed data from the trial, the Times reported.
How does the drug work its magic? It is a monoclonal antibody, a manmade copy of an antibody produced by a patient who recovered from COVID-19, the Times reported. Scientists around the world have high hopes that that monoclonal antibodies will prove to be powerful coronavirus treatments, but they come with a caveat: They are difficult to manufacture, and would take time to produce, the Times reported.
In the trial, 452 newly diagnosed COVID patients received the monoclonal antibody or a placebo infusion. Some 1.7 percent of those who got the drug were hospitalized, compared with 6 percent of those who received a placebo — a 72 percent reduction in risk, Eli Lilly said.
At the same time, blood levels of the coronavirus plummeted among those who received the drug, and their symptoms were fewer and milder, the Times reported.
This is the first treatment aimed at patients who are not already seriously ill and hospitalized, the newspaper added.
Dr. Myron Cohen, director of the Institute for Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill, told the Times he was impressed by the findings.
“It’s exciting,” said Cohen, who was not involved in the study. The trial appears to be rigorous, and the results are “really compelling,” he added. Other monoclonal antibody drugs to combat the coronavirus are in development, he noted.
“This is the opening of a door,” Cohen said.
Most Americans doubt Trump’s vaccine comments
In a sign that Americans are becoming more wary about the safety of a new coronavirus vaccine, a new poll shows a majority of adults don’t trust what President Donald Trump has said on vaccine development.
More than half (52%) of adults said they don’t trust the president’s vaccine comments, the NBC News/Survey Monkey poll found, while just 26% say they do. Twenty percent said they were “not aware” whether they trust what the president has said about a vaccine, NBC News reported.
Those polled were also more skeptical about whether they or their families would get a government-approved coronavirus vaccine if one became widely available, NBC News reported.
The poll’s latest data show that just 39% said they would get it, 23% said they wouldn’t and 36% say they weren’t sure. Just a month ago, 44% of Americans said they would get a government-approved vaccine, 22% said they wouldn’t, and 32% said they weren’t sure.
The highest level of confidence in a coronavirus vaccine came during the week of Aug. 17 to Aug. 23, when 45% polled said they would get a vaccine.
Despite public hesitancy, President Trump has promised a “safe and effective vaccine this year,” and the U.S. Centers for Disease Control and Prevention has advised states to prepare for “large-scale” vaccine distribution by Nov. 1.
Public health experts have questioned that aggressive timeline. Dr. Anthony Fauci, the nation’s leading infectious diseases expert, has said that he feels “cautiously optimistic” that a safe and effective vaccine would be found by the end of the year but that doing so by Nov. 3 was “unlikely,” NBC News reported.
Cases keep mounting
By Thursday, the U.S. coronavirus case count passed 6.6 million as the death toll passed 196,600, according to a Times tally.
According to the same tally, the top five states in coronavirus cases as of Thursday were: California with nearly 773,000; Texas with more than 706,000; Florida with over 671,000; New York with more than 451,000; and Georgia with over 282,000.
Curbing the spread of the coronavirus in the rest of the world remains challenging.
By Thursday, India’s coronavirus case count had passed 5.1 million, just one month after hitting the 3 million mark, the Times reported.
More than 83,000 coronavirus patients have died in India, but when measured as a proportion of the population, the country has had far fewer deaths than many others. Doctors say this reflects India’s younger and leaner population.
The country’s public health system is severely strained, and some sick patients cannot find hospital beds, the newspaper said. Only the United States has more coronavirus cases.
Meanwhile, Brazil posted over 4.4 million cases and over 134,000 deaths as of Thursday, the Times tally showed.
Cases are also spiking in Russia: The country’s coronavirus case count has passed 1 million, the Times reported. As of Thursday, the death toll in Russia was 18,996.
Worldwide, the number of reported infections passed 29.8 million on Thursday, with nearly 941,000 deaths, according to the Hopkins tally.
More information: The U.S. Centers for Disease Control and Prevention has more on the new coronavirus.
SOURCES: The New York Times; CNN; Associated Press;
By Robin Foster and E.J. Mundell HealthDay Reporters
THURSDAY, Aug. 27, 2020 (HealthDay News) — The first rapid coronavirus test that doesn’t need any special computer equipment to produce results was approved by the U.S. Food and Drug Administration on Wednesday.
Made by Abbott Laboratories, the 15-minute test will sell for $5, giving it an edge over similar tests that need to be popped into a small machine, the Associated Press reported. No larger than a credit card, the Abbott test is based on the same technology used to test for the flu, strep throat and other infections.
BinaxNOW is the fourth rapid test in the United States that detects COVID-19 antigens, proteins found on the surface of the coronavirus, rather than the virus itself, the AP reported. It’s considered a faster, but less precise, screening method.
Abbott’s entry into the rapid COVID-19 test market offers yet another option to expand testing, the APreported. The FDA also recently gave its blessing to a saliva test from Yale University that bypasses some of the supplies that have led to testing bottlenecks, the wire service said. Neither test can be performed at home.
But several companies are developing rapid at-home tests, though none have yet won FDA approval, the APreported. Abbott’s new test still requires a nasal swab be taken by a health worker, like most older coronavirus tests. The Yale saliva test eliminates the need for a swab, but can only be run at high-grade laboratories.
Roughly 690,000 Americans are now being tested per day, down from a peak of 850,000 daily tests late last month, the AP reported. But many public health experts believe the country will soon need to test vastly more people as schools reopen and the flu season arrives.
Since the start of the pandemic, nasal swab tests that are sent to a lab have been the standard for COVID-19 screening. While considered highly accurate, the tests rely on expensive, specialized machines and chemicals. Shortages of those supplies have led to repeated delays in reporting results, the AP reported.
“Those [rapid] screening tests are what we need in schools, workplaces and nursing homes in order to catch asymptomatic spreaders,” Dr. Jonathan Quick, of wire service. The nonprofit group has called for the United States to conduct about 4 millions per day by October, mostly rapid, point-of-care tests.
Thousands of cases reported on college campuses
More testing could not come soon enough: Just weeks after colleges across the United States began to reopen their campuses for the fall semester, thousands of coronavirus infections are cropping up in students and staff alike.
More than 1,500 American colleges and universities were tallied in The New York Times survey. That included every four-year public institution, every private college that competes in NCAA sports and others that identified cases. The case total: At least 26,000 cases and 64 deaths have been reported since the pandemic began, the Times reported.
The trend is unfolding everywhere. The University of North Carolina at Chapel Hill sent most undergraduates home after COVID-19 clusters popped up in campus housing. In-person classes were delayed at Notre Dame as students tested positive by the hundreds. Clemson, Baylor, Louisville and dozens of other Division I universities have confirmed COVID-19 cases in their athletic departments. And aggressive testing of students moving into dorms turned up scores of cases at Iowa State, the Times reported.
Meanwhile, the potential of convalescent plasma as a treatment for severe COVID-19 was still unclear Tuesday, as the World Health Organization cautioned the therapy remains experimental and American scientists challenged a key statistic cited by U.S. officials as grounds for emergency approval of the treatment.
In announcing the approval this week, President Donald Trump and two of his top health officials stirred controversy when they used the same statistic — that the treatment had reduced deaths by 35 percent, the Times reported.
Dr. Stephen Hahn, the commissioner of the Food and Drug Administration, went so far as to say that 35 out of 100 COVID-19 patients “would have been saved because of the administration of plasma.”
Levels of risk
But many scientists, including one researcher from the Mayo Clinic study from which the statistic was supposedly gleaned, said Monday they could not ascertain where the number came from, and that Hahn had appeared to overstate the treatment’s benefits, the Times reported.
“Do I know where the 35 percent comes from?” said Dr. Arturo Casadevall, one of the May Clinic study’s main authors who hails from Johns Hopkins University in Baltimore. “No.”
The actual data from the Mayo Clinic study shows that, among a group of more than 35,000 patients, when plasma was given within three day of diagnosis, the death rate was about 22 percent, compared with 27 percent when it was given four or more days after diagnosis, the Times reported.
But Hahn seemed to have instead mixed up absolute risk and relative risk in a small subgroup of patients in the study, the Washington Post reported.
On Monday night, Hahn acknowledged in a tweet that he had misspoken during the Sunday news briefing about the findings of the plasma study.
“I have been criticized for remarks I made Sunday night about the benefits of convalescent plasma. The criticism is entirely justified,” Hahn wrote. “What I should have said better is that the data show a relative risk reduction, not an absolute risk reduction.”
What is the actual benefit? Eric Topol, director of the Scripps Research Translational Institute, said on Twitter Monday that data gathered on the use of plasma in COVID-19 patients indicates that 3 people out of 100 would be saved at seven days of treatment and 5 at 30 days not 35.
Parents overwhelmed as school year starts
Meanwhile, a new survey shows most parents are feeling overwhelmed and abandoned as the school year starts.
Just 1 in 7 parents said their children would be returning to school full time this fall, and most children need help with remote schooling, Times survey released recently found. Yet, 4 in 5 parents said they would have no help in that endeavor, whether from relatives, neighbors, nannies or tutors. As well, more than half of parents said they will be taking on this burden while still holding down paid jobs.
Of course, when both parents are wage earners who need to work outside the home, they cannot be in two places at once. But three-fourths of these parents said they will be overseeing their children’s education, and nearly half plan to handle child care, according to the survey of more than 1,000 parents polled between Aug. 4 and Aug. 8.
Of the parents who are both working remotely during the pandemic, 80 percent will also handle child care and education, the survey showed. One in five are considering hiring a private teacher or tutor to help with remote learning.
“All the choices stink,” Kate Averett, a sociologist at the University at Albany in New York who has been interviewing parents since the spring, told the Times. “There is a lot of stress, a lot of anxiety. Parents tell me about not being able to sleep because they’re so anxious, or tell me they’ve been crying a lot. There’s been a lot of actual crying during interviews.”
By Thursday, the U.S. coronavirus case count passed 5.8 million as the death toll passed 179,000, according to a Times tally.
According to the same tally, the top five states in coronavirus cases as of Thursday were: California with more than 687,000; Texas with more than 619,800; Florida with more than 608,700; New York with over 436,000; and Georgia with more than 244,000.
Nations grapple with pandemic
Elsewhere in the world, the situation remains challenging.
India has passed Britain to have the fourth-highest death toll in the world from the coronavirus, after the United States, Brazil and Mexico, the Post reported.
By Thursday, India had more than 3.3 million confirmed cases of the infection and over 60,000 deaths, a John Hopkins tally shows. Britain remains the worst-hit country in Europe, the Post reported.
Brazil is also a hotspot in the coronavirus pandemic, with over 3.7 million confirmed infections by Thursday, according to the Hopkins tally. It has the second-highest number of cases, behind only the United States.
Cases are also spiking in Russia: As of Wednesday, that country reported the world’s fourth-highest number of COVID-19 cases, at over 972,700, the Hopkins tally showed.
Even New Zealand, a country that hadn’t seen a new coronavirus case in 100 days, hasn’t been spared.
Prime Minister Jacinda Ardern has extended a lockdown in Auckland until Sunday night, the Times reported. The restrictions had been set to expire Wednesday, but Ardern said the extra time was necessary to ensure that a virus cluster of more than 100 cases in Auckland had been brought under control. Arden also said masks were now mandatory on public transportation nationwide.
Worldwide, the number of reported infections passed 24.2 million on Thursday, with more than 826,000 deaths, according to the Hopkins tally.
The U.S. Centers for Disease Control and Prevention has more on the new coronavirus.
SOURCES: Associated Press; The New York Times; Washington Post
As the coronavirus continues to impact families nationwide, the Health Plan wants to be sensitive to the COVID-19 risks related to work, travel, and social distancing. While in person health fairs are being canceled, we wanted to give your employees an opportunity to meet with APWU Health Plan staff virtually. Postal, Federal, and Retirees who are eligible for the Federal Employee Health Benefits Program can access and attend our virtual health fairs safely online.
During Open Season, every Tuesday and Thursday, from 12-2pm EST a Health Plan staff employee will be online to answer questions and discuss plan features. Please forward this email to your employees so that they can participate.
Once registered you will get an email confirmation with a GoToMeeting link and dial-in information. On the Monday before the virtual health fair date you selected, we will email you a reminder and include the dial-in information with instructions.